


|   |  |
|---|--|
| <b>MEDICAL POLICY</b>   | <b>Vitamin D Assay Testing<br/>(Medicare Only)</b> |
| <b>Effective Date:</b> 4/1/2022   | Medical Policy Number: 525                         |
| <br>4/1/2022 | Medical Policy Committee Approved Date: 3/2022     |
| Medical Officer   | Date   |

**See Policy CPT/HCPCS CODE section below for any prior authorization requirements**

## SCOPE:

Providence Health Plan, Providence Health Assurance, Providence Plan Partners, and Ayin Health Solutions as applicable (referred to individually as “Company” and collectively as “Companies”).

## APPLIES TO:

Medicare Only

### MEDICARE POLICY CRITERIA

The following Centers for Medicare & Medicaid Service (CMS) guidelines should be utilized for medical necessity coverage determinations. Click the link provided in the table below to access applicable medical necessity criteria. All listed guidelines apply.

| Service                  | Medicare Guidelines  |
|--------------------------|--|
| <i>Vitamin D Testing</i> | Local Coverage Determination (LCD): Vitamin D Assay Testing ( <a href="#">L34051</a> ) |

## BILLING GUIDELINES

See the associated local coverage article (LCA) for additional billing and coding guidance and utilization (testing frequency) expectations:

- LCA: Billing and Coding: Vitamin D Assay Testing ([A57719](#))

The following CPT/HCPCS codes may be covered when billed with one of the ICD-10 codes included as medically necessary in the Noridian LCA A57719. While these services do not require prior authorization, utilization may be subject to audit and all criteria from LCD L34051 must be met. Thus, inclusion of a diagnosis (ICD-10) code on this list may not warrant coverage.

|                       |  |
|-----------------------|--|
| <b>MEDICAL POLICY</b> | <b>Vitamin D Assay Testing<br/>(Medicare Only)</b> |
|-----------------------|--|

Code 0038U is used to report the Sensieva™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay, by InSource Diagnostics (Monrovia, California). The 20uL serum/plasma method of the Sensieva™ 25OH Vitamin D2/D3 LDT was approved by the Centers for Disease Control and Prevention’s Vitamin D Standardization-Certification Program (CDC VDSCP) in 2017-2018 (CDC, 2019).<sup>1</sup> This test is no longer certified by the CDC’s VDSCP<sup>1</sup> and since that time, the Insource Diagnostics website has been removed. Therefore, it is unknown if this test is still commercially available.

**CPT/HCPCS CODES**

| Medicare Only                   |   |
|---------------------------------|---|
| No Prior Authorization Required |   |
| 0038U                           | Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative |
| 82306                           | Vitamin D; 25 hydroxy, includes fraction(s), if performed                     |
| 82652                           | Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed                |

**INSTRUCTIONS FOR USE**

Company Medical Policies serve as guidance for the administration of plan benefits. Medical policies do not constitute medical advice nor a guarantee of coverage. Company Medical Policies are reviewed annually and are based upon published, peer-reviewed scientific evidence and evidence-based clinical practice guidelines that are available as of the last policy update. The Companies reserve the right to determine the application of Medical Policies and make revisions to Medical Policies at any time. Providers will be given at least 60-days notice of policy changes that are restrictive in nature.

The scope and availability of all plan benefits are determined in accordance with the applicable coverage agreement. Any conflict or variance between the terms of the coverage agreement and Company Medical Policy will be resolved in favor of the coverage agreement.

**REGULATORY STATUS**

Mental Health Parity Statement

Coverage decisions are made on the basis of individualized determinations of medical necessity and the experimental or investigational character of the treatment in the individual case. In cases where medical necessity is not established by policy for specific treatment modalities, evidence not previously considered regarding the efficacy of the modality that is presented shall be given consideration to determine if the policy represents current standards of care.

**REFERENCES**

1. CDC Vitamin D Standardization-Certification Program (CDC VDSCP); Available at: [https://www.cdc.gov/labstandards/pdf/hs/CDC\\_Certified\\_Vitamin\\_D\\_Procedures-508.pdf](https://www.cdc.gov/labstandards/pdf/hs/CDC_Certified_Vitamin_D_Procedures-508.pdf)